Quantcast
Last updated on April 24, 2014 at 16:36 EDT

Latest Porphobilinogen Stories

2012-12-11 04:21:28

AMSTERDAM, December 11, 2012 /PRNewswire/ -- uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient. The study is conducted under the aegis of the AIPGENE consortium, a pan-European collaboration funded in part by the European Commission's Seventh Framework Program with the aim to develop a gene therapy for the treatment of AIP, a rare and...

2011-02-03 08:59:00

MADRID, February 3, 2011 /PRNewswire/ -- Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP). The AIPGENE consortium is led by CIMA...

2011-01-30 23:59:00

AMSTERDAM, The Netherlands, January 31, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Union (EU) has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria (AIP). AIP is a severe and progressive disease caused by the inability of the body to produce the heme protein,...